AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02152345
Drug: Belatacept
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belatacept 10 mg/kg will be administered in the operating room approximately 1 hour prior to kidney allograft reperfusion (Day 0). It will then be administered at 10 mg/kg on the following post-transplantation days: Day 5, 14, 30, 56, and 84.~Belatacept 5 mg/kg will be administered every four weeks thereafter until end of study.
Trial: NCT00447967
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85 mg/m2 as a 4 hour IV infusion, Day 1 every 4 weeks for 6 cycles
Trial: NCT01822665
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol fast dissolving tablets of 500 mg strength
Trial: NCT01828840
Drug: epidural morphine via PCEA
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01828840
Drug: epidural methadone via PCEA
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01828840
Drug: intravenous morphine via PCA
RxNorm normalized name: lauryl PCA
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00198679
Drug: Chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00652171
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
Trial: NCT00948077
Drug: Rifater and EMB
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.~The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.~Treatment A (5th day) ---\> Treatment B (6th day) ; Treatment B (5th day) ---\> Treatment A (6th day)
Trial: NCT00166127
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00959907
Drug: BOTULINUM TOXIN TYPE-A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: On Visit 1 (Day 0):~Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~* Dysport®: 4 units will be injected in the left or right forehead side.~* Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)
Trial: NCT04707079
Drug: Duvelisib
RxNorm normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eligible subjects will be given duvelisib orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
Trial: NCT02152345
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.05 mg/kg by mouth every 12 hours will be on Day 0 after transplantation. It will then be administered at 8-12 ng/mL on the following post-transplantation days: Day 3-90; at 8-10 ng/mL Day 91-180.~Tacrolimus 6 - 8 ng/mL will be administered daily thereafter until end of study.~(standard of care)
Trial: NCT01816048
Drug: TAK-700
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
Trial: NCT00365339
Drug: Atazanavir+Ritonavir+Tenofovir
RxNorm normalized name: atazanavir and ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.
Trial: NCT00365339
Drug: Atazanavir+Ritonavir+Tenofovir+Famotidine
RxNorm normalized name: atazanavir and ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.
Trial: NCT00365339
Drug: Atazanavir+Ritonavir+Tenofovir+Famotidine
RxNorm normalized name: atazanavir and ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.
Trial: NCT00365339
Drug: Atazanavir+Ritonavir+Tenofovir+Famotidine
RxNorm normalized name: atazanavir and ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.
Trial: NCT00365339
Drug: Atazanavir+Ritonavir+Tenofovir+Famotidine
RxNorm normalized name: atazanavir and ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.
Trial: NCT01862081
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive docetaxel 75 milligrams per meter-squared (mg/m\^2) intravenous (IV) dose on Day 1 of each 21-day cycle.
Trial: NCT01862081
Drug: GDC-0032
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.
Trial: NCT01862081
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive paclitaxel 80 mg/m\^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.
Trial: NCT01471964
Drug: MLN8237 and Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib pills once every day and MLN8237 pills twice every day, day 1-7 of every 21 days
Trial: NCT01288157
Drug: Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of 100 mg subcutaneously
Trial: NCT01288157
Drug: Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of 50 mg subcutaneously
Trial: NCT01070979
Drug: Conjugated equine estrogens
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet containing 0.625 mg CEE, daily oral administration.
Trial: NCT01830985
Drug: VX-509
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX-509 dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg, as needed (determined by ongoing disease activity by CDAI)
Trial: NCT02579434
Drug: Midazolam I.V.
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam I.V. 1mg/ml
Trial: NCT00227084
Drug: Arista AH hemostasis powder
RxNorm normalized name: Aristada
DrugBank: Aripiprazole lauroxil (DB14185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02544854
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:~1. First 15 minutes: 15 mg/kg/min~2. 16 to 30 minutes: 13 mg/kg/min~3. 31 to 60 minutes: 11 mg/kg/min~4. 61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.~Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:~1. 5, 15 and 25 minutes of starting infusion,~2. 1, 3, 5, 7, 9 and 12 minutes of bolus and,~3. 5, 25, 60 and 120 minutes of infusion ended.
Trial: NCT01154452
Drug: Vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00777348
Drug: Combination DSCG and Reproterol
RxNorm normalized name: reproterol
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:
Trial: NCT03070990
Drug: Enfortumab vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
Trial: NCT01445847
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/kg or 1 mL/10 kg prior to extubation period. Injection of Lidocaine will be immediately when inhalational agent (Desflurane) is discontinued.
Trial: NCT02015039
Drug: BoNT Injections
RxNorm normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02607436
Drug: Sarpogrelate
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate
Trial: NCT02607436
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin
Trial: NCT00587483
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine is a class I (sodium channel block) antiarrhythmic drug
Trial: NCT00587483
Drug: Amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg
Trial: NCT01392573
Drug: insulin degludec/liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.
Trial: NCT01392573
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.
Trial: NCT00204529
Drug: pegylated interferon-alpha-2a
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00204529
Drug: interferon-alpha-2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02879409
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2,000 mg once daily
Trial: NCT01010672
Drug: Ridaforolimus
RxNorm normalized name: Ridaforolimus
DrugBank: Ridaforolimus (DB06233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus, oral tablet, 40 mg once daily for 5 consecutive days followed by 2-day dosing holiday each week. Participants treated until discontinuation criteria, such as progressive disease or unacceptable toxicity, were met.
Trial: NCT00707993
Drug: Alogliptin
RxNorm normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg, tablets, orally, once daily and glipizide placebo matching tablets, orally, once daily for up to 52 weeks.
Trial: NCT00707993
Drug: Glipizide
RxNorm normalized name: Glipizide
DrugBank: Glipizide (DB01067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin placebo-matching tablets, orally, once daily and glipizide 5 mg to 10 mg, tablets, orally, once daily up to 52 weeks.
Trial: NCT02152345
Drug: Mycophenolate
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An immunosuppressive agent used with other medicines to lower the body's natural immunity in patients who receive kidney transplants.~720 mg by mouth every 12 hours (Day 0)(1080 mg AA).~(standard of care)
Trial: NCT02152345
Drug: rATG
RxNorm normalized name: rATG
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg IV daily on Day 0-3.~(standard of care)
Trial: NCT02152345
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg (Day 0), 250mg (Day 1), 125mg (Day 2), 75 mg (Day 3) IV administered from Day 0-3.~(standard of care)
Trial: NCT00827814
Drug: Dutasteride
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg od.
Trial: NCT02529683
Drug: Nuvaring
RxNorm normalized name: NuvaRing
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: contraceptive vaginal ring with ethinyl estradiol and etonogestrel
Trial: NCT00788060
Drug: Everolimus (RAD001)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg per day, continuously
Trial: NCT00788060
Drug: Sunitinib (Sutent)
RxNorm normalized name: sunitinib Oral Capsule [Sutent]
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 37.5 mg per day, 14 days on, 7 day break
Trial: NCT00014729
Drug: isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00655837
Drug: SGN-40
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-12mg/kg IV; Days 1, 4, 8, 15 and 22 of Cycle 1 and Days 1, 8 and 15 of Cycles 2-8.
Trial: NCT00655837
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8.
Trial: NCT00655837
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles.
Trial: NCT00670930
Drug: omalizumab at a dose of 0.016mg/kg/IU/mL
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02879409
Drug: Gliclazide
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose will be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance. The 30 mg modified-release tablet equals the 80 mg immediate-release tablet.~Immediate-release tablet: Initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80 to 320 mg/day (maximum dose: 320 mg/day); dosage of ≥160 mg should be divided into 2 equal parts for twice-daily administration.~Modified-release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily
Trial: NCT00200967
Drug: salmeterol
RxNorm normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 micrograms (mcg) twice per day (BID) (Serevent 50 mcg diskus, GlaxoSmithKline (GSK), North Carolina)
Trial: NCT01327235
Drug: Endostar
RxNorm normalized name: Endostar
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
Trial: NCT01327235
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
Trial: NCT01444430
Drug: budesonide pMDI
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients were randomized to budesonide and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): budesonide pMDI 80 μg x 2 actuations bid (morning and evening) or budesonide pMDI 160 μg x 2 actuations bid (morning and evening), for oral inhalation.
Trial: NCT02879409
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral: 100 mg once daily
Trial: NCT02879409
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg daily.
Trial: NCT02453555
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02453555
Drug: Empagliflozin placebo + linagliptin placebo low dose
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Matching placebo empagliflozin + linagliptin
Trial: NCT02453555
Drug: Empagliflozin + linagliptin low dose
RxNorm normalized name: empagliflozin / linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablet
Trial: NCT02453555
Drug: Linagliptin placebo
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Matching placebo linagliptin
Trial: NCT02453555
Drug: Empagliflozin + linagliptin high dose
RxNorm normalized name: empagliflozin / linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablet
Trial: NCT03045341
Drug: NB medication (Naltrexone Bupropion combination)
RxNorm normalized name: Nb
DrugBank: Niobium (DB13031)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NB medication
Trial: NCT03468322
Drug: AC-203
RxNorm normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product is formulated as 1% topical ointment
Trial: NCT00500760
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV; in a vein)
Trial: NCT00500760
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously
Trial: NCT01567995
Drug: Clobetasone Butyrate 0.05% Cream
DrugBank: Clobetasone (DB13158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobetasone Butyrate 0.05% Cream
Trial: NCT02879409
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, Monotherapy or combination therapy: 15-30 mg once daily~Patients with heart failure (NYHA Class I or II): Monotherapy or combination therapy: 15 mg once daily
Trial: NCT02879409
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg once daily increasing to 10mg once daily as required
Trial: NCT02879409
Drug: human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: insulin dosage and administration according to physician
Trial: NCT01567995
Drug: Vehicle (base cream)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (base cream)
Trial: NCT03403023
Drug: Restasis
RxNorm normalized name: Restasis
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restasis therapy is given to all of the patients as indicated for moderate-severe DES. TFI imaging is performed before and 3 months after initiation of therapy.
Trial: NCT01212965
Drug: Selenium
RxNorm normalized name: Selenium
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg once a day for 6 months by mouth
Trial: NCT04579666
Drug: Pegcetacoplan (APL-2)
RxNorm normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Complement (C3) Inhibitor
Trial: NCT03794557
Drug: Sterile Water Injection
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Sterile Water Injection
Trial: NCT02480088
Drug: Ramosetron
RxNorm normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: ramosetron 0.3 mg IV 20 min before the end of surgery and 24 h after the surgery
Trial: NCT02480088
Drug: Palonosetron
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: palonosetron 0.075 mg IV 20 min before the end of surgery and 24 h after the surgery.
Trial: NCT00983034
Drug: lansoprazole, amoxicillin, clarithromycin
RxNorm normalized name: Lansoprazole, Amoxicillin, Clarithromycin KIT
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
Trial: NCT00892008
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 75-150 mg BID for at least 2 weeks.